



Meeting rising global demand for faster, better diagnostics to tackle the great health challenges of our time.

Cancer. Cardiovascular disease. Infectious diseases.

EDX Medical develops and supplies best-in-class digitallyenabled testing solutions to transform treatment options.

## EDX Medical Group plc - the company

#### Listed AQSE November 2022 - Market cap c£33m

- Highly experienced leadership & management team with strong track record in delivering shareholder value.
- Rapidly growing company operating in high growth global markets.
- Empowering healthcare professionals with tests and data to deliver truly effective personalised treatment and optimal patient outcomes.
- Combining cutting-edge biological and digital technologies at world class laboratories in Oxford and Cambridge.
- Strong partnerships with life sciences leaders to access global markets.





**CURESPONSE** 









### **Products**

We provide best-in-class point of care and laboratory diagnostics





# Why invest?

A team that has worked together over 35 years, building multiple bioscience businesses that have returned \$3.8bn to investors and founders.



Founder/CSO
Professor Sir Chris Evans
Prolific life-sciences entrepreneur



Chief Executive
Dr Mike Hudson
Scientist & entrepreneur healthcare &
bioscience



Chief Commercial Officer
Eric Vick
25 years' experience
in life sciences



Senior Independent Director Professor Trevor Jones Former R&D Director, Wellcome plc, Commissioner: WHO



Chairman
Jason Holt
Experienced corporate leader,
ex- HM Govt adviser



Lord Andrew Lloyd-Webber Composer, philanthropist



**Sir Tony Gallagher**Businessman, philanthropist



**Steve Morgan CBE**Businessman, philanthropist



**Sir Tom Hunter** – Businessman, philanthropist



Mark McGourty
Private equity



**David Rees**Seerave Foundation

Shares in issue: 350.1m



# Why invest?

Right place, right time – EDX Medical in the vanguard of digital/biohealth advances

- Huge rise globally in personalised medicine has created global growing markets
- The right treatment first time tailored to the patient
   is a rapid upward trend
  - ✓ High-performing AQUIS stock since listing
  - ✓ Outstanding leadership experience
  - **✓ Committed prominent investors**
  - **✓ Strong international partnerships**

The clinical diagnostics market is expected to grow from \$80 billion in 2023 to \$104 billion by 2028, at a CAGR of 5.48%

Burgeoning demand for earlier diagnostic solutions to cut delays and costs in healthcare systems

